Results 1 to 10 of about 6,074,393 (210)

Identification of Contacts With High Rates of Missed and Asymptomatic Infection Following an Outbreak of Ebola Virus Disease: A Seroepidemiological Study in Likati Health Zone, Democratic Republic of the Congo. [PDF]

Open Forum Infect Dis
Tshiani Mbaya O, Ariyoshi K, Skrip L, Kahusu CM, Suangi A, Mubiala A, Tshomba A, Yoshinao K, Mumbere G, Muyembe JJ, Mulangu S.   +10 more
europepmc   +1 more source

Small molecule drug discovery for Ebola virus disease. [PDF]

RSC Med Chem
Durante D, Murugesh V, Kalanquin T, Gaisina IN, Rong L, Moore TW.   +5 more
europepmc   +1 more source

Correction: Spatial modeling and ecological suitability of Ebola virus disease in Africa. [PDF]

PLoS One
Didier LB, Jude LL, Franck EI, Wang H, Wang XL.   +4 more
europepmc   +1 more source

Long-term psychosocial sequelae of Ebola virus disease among survivors compared with contacts following the 2013-2016 epidemic in Liberia. [PDF]

PLOS Glob Public Health
Badio M, Glayweon M, Van Ryn C, Wilson B, Cooper JB, Moses JS, Fayiah T, Johnson K, Gayedyu-Dennis D, Chitre SD, Richardson ET, Reilly C, Weiser SD, Rutherford GW, Fallah MP, Kelly JD.   +15 more
europepmc   +1 more source

Ebola Virus Disease: Uniquely Challenging Among the Viral Hemorrhagic Fevers. [PDF]

Open Forum Infect Dis
Matson MJ, Chertow DS, Munster VJ.
europepmc   +1 more source

Modeling Case Burden and Duration of Sudan Ebola Virus Disease Outbreak in Uganda, 2022. [PDF]

Emerg Infect Dis
Bisanzio D, Bosa HK, Bakamutumaho B, Nasimiyu C, Atwine D, Kyabayinze D, Olaro C, Breiman RF, Njenga MK, Mwebesa H, Aceng JR, Reithinger R.   +11 more
europepmc   +1 more source

Access to licenced vaccines for high-threat infectious diseases: a scoping review and interpretive analysis of Ebola virus disease. [PDF]

BMC Infect Dis
Diepvens C, Guttieres D, De Boeck K, Vandaele N, Guariguata L, Decouttere C.   +5 more
europepmc   +1 more source

Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial. [PDF]

PLoS Negl Trop Dis
Kpetigo AD, Alexandre M, Camara A, Beavogui A, Doumbia S, Kieh M, Leigh B, Sow S, Wittkop L, Soutthiphong AA, Berry IM, Fleck S, Akoo P, Hamze B, Watson-Jones D, Kuhn JH, Greenwood B, Richert L, Yazdanpanah Y, Lévy Y, Thiébaut R, Prague M, PREVAC Study Team, Lhomme E.   +23 more
europepmc   +1 more source